TABLE 3.

Comparison of germline and somatic mutations in BRCA1/2. A, Summary; (B) detailed results of cases

(A) Germline genetic testing a	F1CDx		Total
Oncogenic variant	Oncogenic variant	Not detected
Positive	7	1 b	8
Negative	3	24	27
Not examined	7	67	74
Total	17	92	109

(B) Sample no	Subtype	Germline genetic testing#1		F1CDx
		BRCA1	BRCA2	BRCA1	BRCA2
002	TNBC	G1738R		G1738R	—
007	TNBC	2050delG		C644fs*7	—
026	TNBC	1135insA		V340fs*6	—
028	TNBC	K893fs*106		K893fs*106	—
097	TNBC	C64R		C64R c	—
099	TNBC	Positive		R1085*	—
091	HER2	81‐1G>A		splice site 81‐1G>A	—
201	Luminal B		S547X	—	S547*
004	TNBC	—	—	G275D	—
035	TNBC	—	—	E1011*	—
088	Luminal B	—	—	—	E2474*
029	TNBC	NE	NE	S1374fs*1	—
030	TNBC	NE	NE	truncation exon 10	—
060	TNBC	NE	NE	I1159fs*50	—
040	Luminal B	NE	NE	E111fs*3	—
055	Luminal B	NE	NE	—	R2318*
216	Luminal B	NE	NE	—	R2318*
074	Luminal‐HER2	NE	NE	—	truncation intron 7

Abbreviations: F1CDx, FoundationOne® CDx; HER2, human epidermal receptor type 2; NE, not examined; TNBC, triple‐negative breast cancer.

^aGermline genetic testing included BRACAnalysis and multigene panel testing, myRisk.

^bVariant of unknown significance.

^cThis mutation was found as a variant of unknown of significance in the F1CDx report.